A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs ARGX 110 (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors argenx
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2016 New trial record
- 03 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.